Bio-Pharm Archives - 17 중 5 번째 페이지

LigaChemBio Aims to Secure 20 ADC Pipeline Assets by 2027

Kim Yongzu LigaChemBio. [photo=kormedi.com] LigaChemBio has announced its plan to build a pipeline of 20 antibody-drug conjugate (ADC) assets by 2027. The company intends to accelerate global commercialization by expanding…

Cheon Okhyeon

2025-07-01

Celltrion to Buy Back KRW 100 Billion in Treasury Shares

Celltrion announced on June 26 that its board of directors has approved an additional repurchase of treasury shares worth approximately KRW 100 billion (USD 72 million). The repurchase will be…

Cheon Okhyeon

2025-06-26

Pharos’ AI-Designed Leukemia Drug Earns Orphan Designation in Europe

Pharos iBio, a South Korea-based biotech specializing in AI-driven drug discovery, announced that its lead investigational asset PHI-101, a next-generation therapy for acute myeloid leukemia (AML), has been granted orphan…

Won Jonghyuck

2025-06-24

Hanmi Pharmaceutical reveals Phase 1 results for triple agonist obesity drug HM15275

Hanmi Pharmaceutical has released the first clinical data from its next-generation triple agonist obesity drug, HM15275, showing promising early efficacy with a differentiated approach to muscle-sparing weight loss. At the…

Cheon Okhyeon

2025-06-23

Lotte Biologics Signs CMO Agreement with UK Biotech Firm ‘OTTIMO’

Lotte Biologics has signed a contract manufacturing organization (CMO) agreement with UK-based biotech company OTTIMO Pharma for the production of an antibody drug substance. According to Lotte Biologics on the…

Cheon Okhyeon

2025-06-19

Mini Organs Instead of Mice? Samsung Biologics Joins the Organoid Revolution

The era of developing new drugs without animal testing is becoming a reality. As the U.S. Food and Drug Administration (FDA) moves to phase out mandatory animal testing, “organoids”—also known…

Cheon Okhyeon

2025-06-16

GC Genome Debuts on KOSDAQ, Targets Early Cancer Detection Markets in Japan and U.S.

South Korea-based genomics company GC Genome debuted on the KOSDAQ market on June 11, following a successful IPO that attracted strong interest from global investors. The IPO was the second-largest…

Cheon Okhyeon

2025-06-11

AriBio Signs Alzheimer’s Drug Licensing Deal Worth $600 Million with UAE Pharma Company

AriBio has successfully signed a technology licensing deal worth up to KRW 820 billion (approx. USD 600 million) with a pharmaceutical company based in the Middle East. On June 10,…

Cheon Okhyeon

2025-06-10

K-Bio Showcases Innovation and Pursues One-on-One Partnering at BIO USA

Korean biotech companies are set to make a strong showing at BIO USA 2025, the world’s largest biotech convention, with a focus on technology licensing, global partnerships, and overseas investment.…

Cheon Okhyeon

2025-06-09

PTAB Grants Merck Review of Halozyme Patent Claims, Boosting Alteogen’s Milestone Prospects

The U.S. Patent Trial and Appeal Board (PTAB) has instituted a post-grant review of a key Halozyme patent, following Merck’s petition challenging its validity. The move casts doubt on the…

Cheon Okhyeon

2025-06-04